2023
Human vascularized bile duct-on-a chip: a multi-cellular micro-physiological system for studying cholestatic liver disease
Du Y, de Jong I, Gupta K, Waisbourd-Zinman O, Har-Zahav A, Soroka C, Boyer J, Llewellyn J, Liu C, Naji A, Polacheck W, Wells R. Human vascularized bile duct-on-a chip: a multi-cellular micro-physiological system for studying cholestatic liver disease. Biofabrication 2023, 16: 015004. PMID: 37820623, PMCID: PMC10587873, DOI: 10.1088/1758-5090/ad0261.Peer-Reviewed Original ResearchMeSH KeywordsBile DuctsCholangitis, SclerosingEndothelial CellsHumansLeukocytes, MononuclearLiver DiseasesSignal TransductionConceptsCholestatic liver diseasePrimary sclerosing cholangitisLiver diseaseBile ductBile duct tissuesDuct tissuePeripheral blood mononuclear cellsEndothelial cellsBlood mononuclear cellsNormal bile duct tissuesHuman vascular endothelial cellsVascular endothelial cellsPSC patientsSclerosing cholangitisIL-17ATh17 cellsMononuclear cellsVascular channelsBiliary organoidsCholangiocyte organoidsBlood vesselsCholangiocytesDiseaseFlow of bloodTight junctions
2022
Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases
Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases. Hepatology 2022, 75: 1012-1013. PMID: 34431119, DOI: 10.1002/hep.32117.Peer-Reviewed Original Research
2018
Cenicriviroc, a cytokine receptor antagonist, potentiates all‐trans retinoic acid in reducing liver injury in cholestatic rodents
Yu D, Cai S, Mennone A, Vig P, Boyer JL. Cenicriviroc, a cytokine receptor antagonist, potentiates all‐trans retinoic acid in reducing liver injury in cholestatic rodents. Liver International 2018, 38: 1128-1138. PMID: 29356312, PMCID: PMC6032984, DOI: 10.1111/liv.13698.Peer-Reviewed Original ResearchConceptsBile acid pool sizeTrans retinoic acidAcid pool sizePlasma liver enzymesLiver injurySuperior therapeutic effectLiver necrosisLiver enzymesT cellsTherapeutic effectRetinoic acidAntagonist of CCR2Hepatic inflammatory cellsCholestatic liver injuryBile duct proliferationBody weight ratioCholestatic liver diseasePro-inflammatory cytokinesCytokine receptor antagonistsHepatic hydroxyproline contentExpression of cytokinesDuct-ligated ratsBile acid synthesisHepatic infiltrationLiver disease
2017
Bile acids initiate cholestatic liver injury by triggering a hepatocyte-specific inflammatory response
Cai SY, Ouyang X, Chen Y, Soroka CJ, Wang J, Mennone A, Wang Y, Mehal WZ, Jain D, Boyer JL. Bile acids initiate cholestatic liver injury by triggering a hepatocyte-specific inflammatory response. JCI Insight 2017, 2: e90780. PMID: 28289714, PMCID: PMC5333973, DOI: 10.1172/jci.insight.90780.Peer-Reviewed Original ResearchConceptsLiver injuryInflammatory responseBile acid-induced liver injuryCholestatic liver injuryInflammatory liver injuryProinflammatory cytokine expressionCholestatic liver diseaseBile duct ligationVivo mouse modelHepatic infiltrationInflammatory injurySerum aminotransferasesLiver diseaseCholestatic patientsCytokine expressionChemokine inductionPathophysiologic concentrationsNeutrophil chemotaxisDuct ligationPathophysiologic levelsMouse modelNew therapiesInnate immunityInjuryPeriportal areas
2016
Sirtuin 1 activation alleviates cholestatic liver injury in a cholic acid–fed mouse model of cholestasis
Kulkarni SR, Soroka CJ, Hagey LR, Boyer JL. Sirtuin 1 activation alleviates cholestatic liver injury in a cholic acid–fed mouse model of cholestasis. Hepatology 2016, 64: 2151-2164. PMID: 27639250, PMCID: PMC5115990, DOI: 10.1002/hep.28826.Peer-Reviewed Original ResearchConceptsCholestatic liver injuryLiver injurySRT1720 administrationSIRT1 expressionCa dietMouse modelFibroblast growth factor 15Proliferator-activated receptor gamma coactivator 1Multidrug resistance-associated protein 2Peroxisome proliferator-activated receptor gamma coactivator 1Hepatic BA compositionHepatic BA synthesisGrowth factor 15Receptor gamma coactivator 1Resistance-associated protein 2Plasma alanine aminotransferasePlasma BA concentrationsCultured primary human hepatocytesNovel therapeutic targetSirtuin 1 activationFarnesoid X receptorMiR-34a expressionSIRT1 messenger RNACytochrome P450 7A1Bile acid sensor
2015
Na+/H+ exchanger regulatory factor 1 knockout mice have an attenuated hepatic inflammatory response and are protected from cholestatic liver injury
Li M, Mennone A, Soroka CJ, Hagey LR, Ouyang X, Weinman EJ, Boyer JL. Na+/H+ exchanger regulatory factor 1 knockout mice have an attenuated hepatic inflammatory response and are protected from cholestatic liver injury. Hepatology 2015, 62: 1227-1236. PMID: 26108984, PMCID: PMC4589453, DOI: 10.1002/hep.27956.Peer-Reviewed Original ResearchConceptsBile duct ligationLiver injuryInflammatory responseICAM-1BDL miceBDL-induced liver injuryNeutrophil-mediated liver injuryTotal bile acid concentrationTumor necrosis factor alphaIntercellular adhesion molecule-1Hepatic neutrophil accumulationAttenuated liver injuryCholestatic liver injuryHepatic inflammatory responseMouse liverSerum alanine aminotransferaseBile acid concentrationsHepatic inflammatory diseasesICAM-1 expressionNecrosis factor alphaAdhesion molecule-1Wild-type miceICAM-1 proteinNew therapeutic targetsMessenger RNA levels
2011
Drug‐induced cholestasis
Padda MS, Sanchez M, Akhtar AJ, Boyer JL. Drug‐induced cholestasis. Hepatology 2011, 53: 1377-1387. PMID: 21480339, PMCID: PMC3089004, DOI: 10.1002/hep.24229.Peer-Reviewed Original Research
1981
Prognostic indicators of hepatic injury following jejunoileal bypass performed for refractory obesity: A prospective study
Haines N, Baker A, Boyer J, Glagov S, Schneir H, Jaspan J, Ferguson D. Prognostic indicators of hepatic injury following jejunoileal bypass performed for refractory obesity: A prospective study. Hepatology 1981, 1: 161-167. PMID: 7286895, DOI: 10.1002/hep.1840010212.Peer-Reviewed Original ResearchConceptsJejunoileal bypassInactive cirrhosisWeight lossHepatic injuryLiver biopsyPericentral fibrosisClinical liver failureOral nutritional supplementationAlcoholic liver diseaseSerum aspartate aminotransferaseGreater weight lossRapid weight lossCryptogenic cirrhosisRefractory obesityAsymptomatic patientsOlder patientsLiver failureLiver injuryLiver diseaseParenteral alimentationFatty infiltrationHistologic evidenceProspective studyPrognostic indicatorClinical evaluation
1978
Validation of 13CO2 breath analysis as a measurement of demethylation of stable isotope labeled aminopyrine in man
Schneider J, Schoeller D, Nemchausky B, Boyer J, Klein P. Validation of 13CO2 breath analysis as a measurement of demethylation of stable isotope labeled aminopyrine in man. Clinica Chimica Acta 1978, 84: 153-162. PMID: 639299, DOI: 10.1016/0009-8981(78)90489-8.Peer-Reviewed Original ResearchConceptsLiver diseaseHepatic microsomal drug metabolismMicrosomal drug metabolismSimultaneous oral administrationDrug-drug interactionsNon-invasive assessmentN-demethylation activityOral doseCumulative excretionOral administrationEffects of diseaseExcretion of labelAdult subjectsDrug metabolismDiseaseExpired breathCumulative appearanceHuman subjectsPatientsReproducible increaseAminopyrineRadiation riskExcretionSubjectsHours
1974
Ultrastructural changes in livers of two patients with hypervitaminosis A.
Hruban Z, Russell R, Boyer J, Glagov S, Bagheri S. Ultrastructural changes in livers of two patients with hypervitaminosis A. American Journal Of Pathology 1974, 76: 451-61. PMID: 4416771, PMCID: PMC1910880.Peer-Reviewed Original ResearchConceptsPerisinusoidal fibrosisDistinctive ultrastructural changesChronic hypervitaminosis ALipid-storing cellsUltrastructural changesHypervitaminosis AHypervitaminosis A.Blood flowCellular atrophyFibrosisIto cellsMesenchymal cellsPatientsBasement membraneLiverMassive accumulationCellsNumerous bundlesAtrophyLymphocytesBullaeImpairment